ArticleFrontiers in oncology2023

Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy.

Michael R Sayer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.